Firmonertinib
FURMO-005
Phase 3 small_molecule active
Quick answer
Firmonertinib for NSCLC is a Phase 3 program (small_molecule) at ArriVent BioPharma with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ArriVent BioPharma
- Indication
- NSCLC
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active